Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
10300
¥ million (change in net sales)Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending March 2027 · Cumulative second quarter and full yearPrevious forecast published 12 May 2026Net SalesCumulative second-quarter results123,500→133,800million
+8.3%
Net SalesFull year260,600→270,900million
+4.0%
Operating profitCumulative second-quarter results11,800→13,700million
+16.1%
Operating profitFull year25,400→27,300million
+7.5%
Ordinary incomeCumulative second-quarter results11,900→13,800million
+16.0%
Ordinary incomeFull year25,200→27,000million
+7.1%
Profit attributable to owners of the parentCumulative second-quarter results11,800→13,100million
+11.0%
Profit attributable to owners of the parentFull year22,300→22,900million
+2.7%
Net income per shareCumulative second-quarter results80.49→89.35yen and sen
+11.0%
Net income per shareFull year154.5→158.66yen and sen
+2.7%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
For the cumulative second quarter, each earnings figure is expected to exceed the previous forecast, owing to strong sales in the Safety Systems, Functional Materials and Pharmaceuticals businesses, as well as foreign exchange rates remaining weaker against the yen than assumed. The full-year forecast reflects the revisions to the cumulative second-quarter forecast.
Previous-period resultsSecond quarter (fiscal year ended March 2026) Net Sales 113,575 / Operating profit 10,618 / Ordinary income 10,843 / Profit attributable to owners of parent for the quarter 11,689 / Net income per share for the quarter ¥75.07 / Full year (fiscal year ending March 2026) Net Sales 241,851 / Operating profit 22,454 / Ordinary income 25,478 / Profit attributable to owners of the parent 24,641 / Net income per share ¥161.18
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | Cumulative second-quarter results 123,500 / Full year 260,600 → Cumulative second-quarter results 133,800 / Full year 270,900（Cumulative second-quarter results 8.3 / Full year 4） |
| Operating profit | Cumulative second-quarter results 11,800 / Full year 25,400 → Cumulative second-quarter results 13,700 / Full year 27,300（Cumulative second-quarter results 16.1 / Full year 7.5） |
| Ordinary income | Cumulative second-quarter results 11,900 / Full year 25,200 → Cumulative second-quarter results 13,800 / Full year 27,000（Cumulative second-quarter results 16 / Full year 7.1） |
| Profit attributable to owners of the parent | Cumulative second-quarter results 11,800 / Full year 22,300 → Cumulative second-quarter results 13,100 / Full year 22,900（Cumulative second-quarter results 11 / Full year 2.7） |
| Net income per share | Cumulative second-quarter results 80.49 / Full year 154.50 → Cumulative second-quarter results 89.35 / Full year 158.66 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Cumulative second quarter and full year |
| Publication date of previous forecast | 12 May 2026 |
| Previous-period results | Second quarter (fiscal year ended March 2026) Net Sales 113,575 / Operating profit 10,618 / Ordinary income 10,843 / Profit attributable to owners of parent for the quarter 11,689 / Net income per share for the quarter ¥75.07 / Full year (fiscal year ending March 2026) Net Sales 241,851 / Operating profit 22,454 / Ordinary income 25,478 / Profit attributable to owners of the parent 24,641 / Net income per share ¥161.18 |
| Reason for the revision | For the cumulative second quarter, each earnings figure is expected to exceed the previous forecast, owing to strong sales in the Safety Systems, Functional Materials and Pharmaceuticals businesses, as well as foreign exchange rates remaining weaker against the yen than assumed. The full-year forecast reflects the revisions to the cumulative second-quarter forecast. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales in the Safety Systems, Functional Materials and Pharmaceuticals businesses have remained strong, while foreign exchange rates have remained weaker against the yen than assumed. The full-year forecast reflects the revisions to the cumulative second-quarter forecast.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.